LV101R

LV101R is an orally administered small molecule cancer therapy being developed by LivFul, Inc., primarily targeting gastrointestinal and colorectal cancers. Preclinical data indicates that the compound exhibits both anti-tumor and anti-angiogenic activities, effectively suppressing tumor growth and reducing tumor volume in animal models. The drug is designed as a safe, broad-spectrum oncology treatment and is currently undergoing early-stage clinical trials in Brazil. LivFul's development strategy focuses on bringing transformative medicines to underserved populations in the global south by conducting high-standard clinical research in cost-effective regions.